CDK6 and chronic myelogenous leukemia, BCR-ABL1 positive: Within the Chronic Myeloid Leukemia, CDK6 (hsa05220 and hsa04110) was progressively down-regulated from diagnosis to 12 months of nilotinib treatment and further underexpressed in CTRLs, exhibiting a high fold change, as previously described (Table S1).